DS
Therapeutic Areas
Alembic Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bevacizumab Biosimilar | Oncology (Various Cancers) | Phase 3 |
| Pegfilgrastim Biosimilar | Chemotherapy-induced Neutropenia | Phase 3 |
| Cardiovascular Generics Portfolio | Hypertension, Heart Failure | Filed/Approved |
| Anti-diabetic Generics Portfolio | Type 2 Diabetes | Filed/Approved |
| CNS Generics Portfolio | Depression, Psychosis, Epilepsy | Filed/Approved |
| Anti-infective Generics Portfolio | Bacterial, Fungal Infections | Filed/Approved |
| Inhalation Products (e.g., Budesonide) | Asthma, COPD | Filed/Development |
| Transdermal Patches | Pain Management | Development |
Leadership Team at Alembic Pharmaceuticals
CA
Chirayu Amin
Executive Chairman
PA
Pranav Amin
Managing Director & CEO
SA
Shaunak Amin
Joint Managing Director & CEO
SK
S. K. Rai
Whole-time Director & President (API & International Business)
RK
R. K. Baheti
Chief Financial Officer (CFO)
DJ
D. J. Shah
Company Secretary & Compliance Officer
DB
Dr. B. N. Singh
President - R&D (API)
AS
A. S. Pillai
President - Manufacturing (Formulations)
RG
R. G. Bhansali
President - Corporate Affairs
P(
Prof. (Dr.) M. D. Nair
Independent Director